Cancer Vaccines: Tumor Epitopes and Gene Therapy

  • George C. Fareed
  • Lynn E. Spitler


Recent progress in our understanding of the molecular biology of the human immune system and the interplay of soluble growth factors, cytokines and lymphokines, to directly activate immune responses coupled with the molecular characterization of tumor antigens in several human cancers now provide for exciting new treatment approaches for cancer immunotherapy. Many groups are now focusing on overcoming the 4 weak tumor-associated’ immunity due to insufficient stimulation of helper T lymphocytes through approaches summarized in this chapter


Melanoma Cell Human Leukocyte Antigen Cancer Vaccine Human Immune Deficiency Virus Recombinant Vaccinia Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abergel C, Loret E, Claverie, J-M. Conformational analysis of T immunogenic peptides by circular dichroism spectroscopy. Eur J Immunol 1989; 19: 1969–1972.PubMedGoogle Scholar
  2. 2.
    Abdel-Wahab Z, Li WP, Osanto S, et al. Cancer Res 1994; 54(1): 182–189.Google Scholar
  3. 3.
    Ada GL. Antigen presentation and enhancement of immunity: An introduction. In: Vaccines 86: New Approaches to Immunization, edited by F. Brown, R.M. Channock, and R. A. Lerner, pp. 105-111. Cold Spring Harbor Laboratories, 1986.Google Scholar
  4. 4.
    Adorini L, Appella E, Doria G, Nagy ZA. Mechanisms influencing the immunodominance of T cell determinants. J Exp Med 1988; 168: 2091–2104.PubMedGoogle Scholar
  5. 5.
    Aisenber AC, Krontires TG, Mak TW, et al. Rearrangement of the gene for the beta chain of the T-cell receptor in T-cell chronic lymphocytic leukemia and related disorders. N Engl J Med 1985; 313: 529–543.Google Scholar
  6. 6.
    Alexander MA, Bennicelli J, Guerry IV, D. Defective antigen presentation by human melanoma cell lines cultured from advanced, but not biologically early, disease. J Immunol 1989; 142:4070–4078.PubMedGoogle Scholar
  7. 7.
    Anderson DJ, Berkowitz RS. γ-Interferon enhances expression of class I MHC antigens in the weakly HLA+ human choriocarcinoma cell line BeWo, but does not induce MHC expression in the HLA+choriocarcinoma cell lin q.J Immunol 1985; 135:2498–2501.PubMedGoogle Scholar
  8. 8.
    Abdel-Wahab Z, Li WP, Osanto S, Darrow TL, et al. Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumor immunity: a nude mouse model. Cell Immunol 1994 Nov; 159(1): 26–39.PubMedGoogle Scholar
  9. 9.
    Andreasen RB, Olsson L. Antibody-producing humanhuman hybridomas III. Derivation and characterization of two antibodies with specificity for human myeloid cells. J Immunol 1986; 137: 1083–1090.PubMedGoogle Scholar
  10. 10.
    Ansel S and Blangy D. In vivo induction of tumor-specific immunity by glycolip extracts of SV40-transformed cells. Int J Cancer 1984; 34: 555–559.PubMedGoogle Scholar
  11. 11.
    Antonia SJ, Uchida J, Cohen S, Cohen MC. Attachment of tumor cells to endothelial monolayers: detection of surface molecules involved in cell-cell binding. Clinical Immunology and Immunopathology 1989; 53: 281–296.PubMedGoogle Scholar
  12. 12.
    Austin EB, Robins RA, Durrant LG, Price MR, et al. Human monoclonal anti-idiotypic antibody to the tumourassociated antibody 791T/36. Immunology 1989; 67: 525–530.PubMedGoogle Scholar
  13. 13.
    Balloul JM, Acres RB, Geist M, et al. Cell Mol Biol (Noisy-le-grand) 1994; 4) Suppl 1:49–59.Google Scholar
  14. 14.
    Barth A, Hoon DS, Foshag LJ, et al. Cancer Res 1994; 54(13) 3342–3345.PubMedGoogle Scholar
  15. 15.
    Berd D, Maguire HC Jr, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 1986; 46: 2572–2577.PubMedGoogle Scholar
  16. 16.
    Berd D, Maguire HC Jr, Mastrangelo MJ, Murphy G. Cancer Immunol Immunother 1994; 39(3) 141–147.PubMedGoogle Scholar
  17. 17.
    Berzofsky JA. Immunogenicity of antigens recognized by T cells. J Cell Biochem 1990; Sup 14B: 50.Google Scholar
  18. 18.
    Blankenstein T. Observations with tumour necrosis factor gene-transfected tumours. Folia Bioil (Praha) 1994; 40(1- 2): 19–28.Google Scholar
  19. 19.
    Bodmer WF. Genetic susceptibility to cancer. In: Accomplishments in Cancer Research 1985, edited by JG Fortner and JE Rhoads, pp. 198–211. Philadelphia, Lippincott, 1986.Google Scholar
  20. 20.
    Bonnefoy J-Y, Denoroy M-C, Guillot O, et al. Activation of normal human B cells through their antigen receptor induces membrane expression of IL-1 a and secretion of IL-lp.JImmunol 1989; 143: 864–869.Google Scholar
  21. 21.
    Brett SJ, Cease KB, Ouyang CS, Berzofsky JA. Fine specificity of T cell recognition of the same peptide in association with different I-A molecules. J Immunol 1989; 143:771–779.PubMedGoogle Scholar
  22. 22.
    Bruland OS, Fodstad O, Stenwig AE, Pihl A. Expression and characteristics of a novel human osteosarcomaassociated cell surface antigen. Cancer Res 1988; 48: 5302–5309.PubMedGoogle Scholar
  23. 23.
    Bystryn JC, Jacobsen S, Harris M, et al. Preparation and characterization of a polyvalent human melanoma antigen vaccine. J Biol Resp Modif 1986; 5: 211–224.Google Scholar
  24. 24.
    Chen J-J, Saeki Y, Shi L, Kohler H. Tumor idiotype vaccines: VI. Synergistic anti-tumor effects with combined ’internal image’ anti-idiotypes and chemotherapy. J Immunol 1989; 143:1053–1057.PubMedGoogle Scholar
  25. 25.
    Chen L, Ashe S, Brady W,etal.Cell 1991; 71: 1093–1099.Google Scholar
  26. 26.
    Crowley NJ, Slingluff Jr CL, Darrow TL, Seigler HF. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic malanomas. Cancer Res 1990; 50:492–498.PubMedGoogle Scholar
  27. 27.
    DuBois GC, Appella E, Law LW. Isolation of a tumorassociated transplantation antigen (TATA) from an SV40 induced sarcoma. Resemblance to the TATA of chemically induced neoplasms. Int J Cancer 1984; 34: 561–566.Google Scholar
  28. 28.
    DuBois GC, Law LW, Appella E. Purification and biochemical properties of tumor-associated transplantation antigens from methylcholanthrene-induced murine sarcomas. Proc Natl Acad Sci (USA) 1982; 79: 7669–7673.Google Scholar
  29. 29.
    Durrant LG, Byers VS, Scannon PJ, et al. Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients. Clin exp Immunol 1989; 75: 258–264.PubMedGoogle Scholar
  30. 30.
    Eggers AE. Use of adult fibroblasts coupled to muramyl dipeptide to induce antitumor immunity. J Biol Resp Modif 1988; 7: 229–233.Google Scholar
  31. 31.
    Eisenbach L, Hollander N, Greenfeld L, et al. The differential expression of H2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int J Cancer 1984; 34: 567–573.PubMedGoogle Scholar
  32. 32.
    Estin CD, Stevenson US, Plowman GD, et al. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci (USA) 1988; 85: 1052–1056.Google Scholar
  33. 33.
    Estin CD, Stevenson U, Kahn M, et al. Transfected mouse melanoma lines that express various levels of melanomaassociated antigen p97. J Nat Cancer Inst 1989; 81: 445–448.PubMedGoogle Scholar
  34. 34.
    Fareed GC, Lee J-H, Ghosh-Dastidar P, et al. Human tumor regression-associated antigenic determinants. In: Human Tumor Antigens and Specific Tumor Therapy, edited by RS Metzgar and MS Mitchell, pp. 317–334. New York, Alan R Liss Inc., 1989.Google Scholar
  35. 35.
    Fareed GC, Mendiaz E, Sen A, et al. Novel antigenic markers of human tumor regression. J Biol Resp Modif 1988; 7: 11–23.Google Scholar
  36. 36.
    Fearon ER, Itaya T, Hunt B, et al. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res 1988; 48:2975–2980.PubMedGoogle Scholar
  37. 37.
    Ferrone S, Chen G, Yang H, et al. Murine antiidiotype monoclonal antibodies in melanoma: immunochemical characterization and clinical applications. J Cell Biochem Sup 1990; 14B: 55.Google Scholar
  38. 38.
    Forni G, Giovarelli M, Cavallo F, et al. J Immunother 1993; 14(4) 253–257.Google Scholar
  39. 39.
    Fradet Y, Cordon-Cardo C, Thomson T, et al. Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci (USA) 1984; 81:224–228.Google Scholar
  40. 40.
    Fujiwara H, Yoshioka T, Kosugi A, et al. Mechanisms for recognition of tumor antigens and implementation of antitumor function by non-cytolytic type of T cells. Gann Monograph on Cancer Research 1988; 34: 71–86.Google Scholar
  41. 41.
    Fujiwara H, Yoshioka T, Shima J, et al. Helper T cell against tumor-associated antigens (TAA): Preferential induction of helper T cell activities involved in anti-TAA cytotoxic and antibody responses. J Immunol 1986; 136: 2715–2719.PubMedGoogle Scholar
  42. 42.
    Gelman IM, Hanafusa H. Immune regression of Rous sarcoma virus-induced tumors: correlation with MMC class I expression. J Cell Biochem Sup 1990; 14B: 96.Google Scholar
  43. 43.
    Gendler S, Taylor-Papadimitriou J, Duhig T, et al. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988; 263:12820–12823.PubMedGoogle Scholar
  44. 44.
    Giacomini P, Imberti L, Adriano A, et al. Immunochemical analysis of the modulation of human melanomaassociated antigens by DNA recombinant immune interferon. JImmunol 1985; 135: 2887–2894.Google Scholar
  45. 45.
    Guo Y, Wu M, Chen H, et al. Science 1994; 263(5146) 518–520.PubMedGoogle Scholar
  46. 46.
    Guttinger M, Certa U, Pink JR, Sinigaglia F. Requirements for screening recombinant DNA libraries for T cell epitope expression. J Immunol Methods 1989; 121: 225–230.PubMedGoogle Scholar
  47. 47.
    Hamaoka T, Kosugi A, Shima J, et al. T-T cell interaction for the augmented induction of anti-tumor protective immunity and its application to active immunotherapy in tumor-bearing hosts. Gann Monograph on Cancer Research 1988; 34: 81–90.Google Scholar
  48. 48.
    Haspel MV, McCabe RP, Pomato N, et al. Generation of tumor cell reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res 1985; 45: 3951–3961.PubMedGoogle Scholar
  49. 49.
    Hearing VJ, Gersten DM, Montague PM, et al. Murine melanoma-specific tumor rejection activity elicited by a purified, melanoma-associated antigen. J Immunol 1986; 137: 379–384.PubMedGoogle Scholar
  50. 50.
    Heicappell R, Shirrmacher V, vonHoegen P, et al. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. 1. Parameters for optimal therapeutic effect. Int J Cancer 1986; 37: 569–577.PubMedGoogle Scholar
  51. 51.
    Hellstrom I, Beaumier PL, Hellstrom KE. Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci (USA) 1986; 83: 7059–7063.Google Scholar
  52. 52.
    Herlyn D. Anti-idiotypes in cancer patients. J Cell Biochem Supp 1990; 14B: 56.Google Scholar
  53. 53.
    Herlyn M, Koprowski H. Melanoma antigens: immunological and biological characterization and clinical significance. Annu Rev Immunol 1988; 6: 283–308.PubMedGoogle Scholar
  54. 54.
    Heyderman E, Chapman DV, Richardson TC, et al. Human chorionic gonadotropin and human placental lactogen in extragonadal tumors. Cancer 1985; 56: 2674–2682.PubMedGoogle Scholar
  55. 55.
    Hostetler LW, Ananthaswamy HN, Kripke ML. Generation of tumor-specific transplantation antigens by UV radiation can occur independently of neoplastic transformation. J Immunol 1986; 137: 2721–2725.PubMedGoogle Scholar
  56. 56.
    Hotta H, Ross AH, Huebner K, et al. Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Res 1988; 48: 2955–2962.PubMedGoogle Scholar
  57. 57.
    Huse WD, Sastry L, Iverson SA, et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 1989; 246: 1275–1281.PubMedGoogle Scholar
  58. 58.
    Imam A, Mitchell MS, Modlin RL, et al. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections. J Invest Dermatol 1986; 86: 145–148.PubMedGoogle Scholar
  59. 59.
    Irie RF, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci (USA) 1986; 83: 8694–8698.Google Scholar
  60. 60.
    Jarrett W, Jarrett O, Mackey L, et al. Vaccination against feline leukemia virus using a cell membrane antigen system. Int J Cancer 1975; 16:134–141.PubMedGoogle Scholar
  61. 61.
    Jeglum KA, Mangan C, Wheeler JE. Enhanced antitumor effects with intralymphatic delivery using bacillus Calmette-Guerin in animal models. Cancer Drug Deliv 1985;2:127–132.PubMedGoogle Scholar
  62. 62.
    Jessup JM, McBride CM, Ames FC, et al. Active specific immunotherapy of Dukes B2 and C colorectal carcinoma: Comparison of two doses of the vaccine. Cancer Immunol Immunother 1986; 21: 233–239.PubMedGoogle Scholar
  63. 63.
    Juillard GJF, Boyer PJJ, Yamashiro CH. A phase 1 study of active specific intralymphatic immunotherapy (ASILI). Cancer 1978; 41: 2215–2225.PubMedGoogle Scholar
  64. 64.
    Kahn M, Hellstrom I, Estin CD, Hellstrom KE. Monoclonal antiidiotypic antibodies to the p97 human melanoma antigen. Cancer Res 1989; 49: 3157–3162.PubMedGoogle Scholar
  65. 65.
    Kan-Mitchell J, Imam S, Kempf RA, et al. Human monoclonal antibodies directed against melanoma tumorassociated antigens. Cancer Res 1986; 46: 2490–2496.PubMedGoogle Scholar
  66. 66.
    Kan-Mitchell J, Kempf RA, Imam A, et al. Monoclonal antibodies in the development of active specific immunotherapy for melanoma. In: Monoclonal Antibodies and Cancer Therapy, edited by RA Reisfeld and S Sell, pp. 523–536. New York, Alan R. Liss, 1985.Google Scholar
  67. 67.
    Kast WM, Offinger R, Peters PJ, et al. Eradication of adenovirus El-induced tumors by El A specific CTL.J Cell Biochem Sup 1990; 14B: 97.Google Scholar
  68. 68.
    Katz J, Bonavida B. A spontaneous sarcoma dependent on host tumor-specific immune lymphocytes. BioEssays 1989; 11:243–250.Google Scholar
  69. 69.
    Kennedy RC, Dreesman GR, Butel JS, et al. Suppression of in vivo tumor formation induced by simian virus 40- transformed cells in mice receiving antiidiotypic antibodies. J Exp Med 1985; 161: 1432–1441.PubMedGoogle Scholar
  70. 70.
    Kennel SJ, Foote LJ, Falcioni R, et al. Analysis of the tumor-associated antigen TSP-180. J Biol Chem 1989; 264:15515–15521.PubMedGoogle Scholar
  71. 71.
    Key MD, Brandhorst JS, Hanna MG. More of the relevance of animal tumor models: immunogenicity of transplantable leukemias of recent origin in syngeneic strain 2 guinea pigs. JBiolResp Modif 1984; 3: 359–365.Google Scholar
  72. 72.
    Key ME, Hoover HC, Hanna MG. Active specific immunotherapy as an adjunct to the treatment of metastatic solid tumors; present and future prospects. Adv Immunol Cancer Ther 1985; 1: 195–219.Google Scholar
  73. 73.
    Kilgus J, Romagnoli P, Guttinger M, et al. Vaccine T-cell epitope selection by a peptide competition assay. Proc Natl Acad Sci (USA) 1989; 86: 1629–1633.Google Scholar
  74. 74.
    KimTS, Cohne EP. Cancer Res 1994; 54(10) 2531–2550.PubMedGoogle Scholar
  75. 75.
    Klagsbrun M, Sasse J, Sullivan R, et al. Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc Natl Acad Sci (USA) 1986; 83: 2448–2452.Google Scholar
  76. 76.
    Klein G, Klein E. Evolution of tumours and the impact of molecular oncology. Nature 1985; 315: 190–195.PubMedGoogle Scholar
  77. 77.
    Kurisu H, Matsuyama H, Ohmoto Y, et al. Cancer Immunol Immunother 1994; 39(4) 249–253.PubMedGoogle Scholar
  78. 78.
    Lamb JR, Ivanyi J, Rees ADM, et al. Mapping of T cell epitopes using recombinant antigens and synthetic peptides. EMBOJ 1987; 6:1245–1249.PubMedGoogle Scholar
  79. 79.
    Lee VK, Harriott TG, Kuchroo VJ, et al. Monoclonal antiidiotypic antibodies related to a murine oncofetal bladder tumor antigen induce specific cell-mediated tumor immunity. Proc Natl Acad Sci (USA) 1985; 82: 6286–6290.Google Scholar
  80. 80.
    Liang S, Linnenbach A, Zell T, et al. Murine melanoma cells transformed with a human melanoma-derived gene: an experimental model for active immunotherapy of human melanoma. J Cell Biochem Sup 1990; 14B: 98.Google Scholar
  81. 81.
    Linnenbach AJ, Wojcierowski J, Wu S, et al. Sequence investigation of the major gastrointestinal tumorassociated antigen gene family, GA733. Proc Nad Acad Sci (USA) 1989; 86:27–31.Google Scholar
  82. 82.
    Livingston PO, Takeyama H, Pollack MS. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. Int J Cancer 1983; 32: 567–575.Google Scholar
  83. 83.
    Longenecker BM, Koganty R, MacLean GD. Adv Exp Med Biol 1994; 353: 105–124.PubMedGoogle Scholar
  84. 84.
    Lopez de Castro JA. Purification of human HLA-A and HLA-B class I histocompatibility antigens. Methods Enzymol 1984; 108: 582–606.Google Scholar
  85. 85.
    Luner SJ, deVellis J. Immunoprecipitation of a MR 64, 000 glial tumor-associated antigen by monoclonal antibody 217C. Cancer Res 1986; 46: 863–865.PubMedGoogle Scholar
  86. 86.
    M araskovsky E, Chen W-F, Shortman K. IL-2 and IFN-y are two necessary lymphokines in the development of cytolytic T cells. J mmunol 1989; 143: 1210–1214.Google Scholar
  87. 87.
    McBride OW, Merry D, Givol D. The gene for human p53 cellular tumor antigen is located on chromosome 17, short arm (17pl3). Proc Natl Acad Sci (USA) 1986; 83: 130– 134.Google Scholar
  88. 88.
    McDonnell JM, Ma yr AJ, Martin WJ. DNA of human papillomavirus type 16 in dysplastic and malignant lesions of the conjunctiva and cornea. N Engl J Med 1989; 320: 1442–1445.PubMedGoogle Scholar
  89. 89.
    McKenzie IFC, Xing P-X, Reynolds K, et al. Design of synthetic peptides for breast cancer. J Cell Biochem Sup 1990; 14B: 346.Google Scholar
  90. 90.
    Milich DR, Hughes JL, McLachlan A, et al. Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope. Proc Natl Acad Sci (USA) 1988; 85: 1610–1614.Google Scholar
  91. 91.
    Miller RA, Maloney DG, Warnke R, et al. Treatment of Bcell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306: 517–522.PubMedGoogle Scholar
  92. 92.
    Milstein C. From the structure of antibodies to the diversification of the immune response. EMBO J 1985; 4: 1083–1092.PubMedGoogle Scholar
  93. 93.
    Minato N. Natural killer cells: characteristics and their role in anti-tumor resistance. Gann Monograph on Cancer Research 1988; 34: 99–123.Google Scholar
  94. 94.
    Moy PM, Golub SH, Calkins E, et al. Effects of intralymphatic immunotherapy on natural killer activity in malignant melanoma patients. J Surg Oncol 1985; 29: 112–117.PubMedGoogle Scholar
  95. 95.
    Nabholz M, MacDonald RD. Cytolytic T Lymphocytes. Annu Rev Immunol 1983; 1: 273–306.PubMedGoogle Scholar
  96. 96.
    Natali PG, Giacomini P, Bigotti A, et al. Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res 1983; 43: 660–668.PubMedGoogle Scholar
  97. 97.
    Natali PG, Nicotra MR, Bigotti A, et al. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci (USA) 1989; 86: 6719–6723.Google Scholar
  98. 98.
    Nudelman ED, Mandel U, Levery SB, et al. A deries of disialogangliosides with binary 2→3 sialosyllactosamine structure, defined by monoclonal antibody NUH2, are oncodevelopmentally regulated antigens. J Biol Chem 1989; 264:18719–18725.PubMedGoogle Scholar
  99. 99.
    Nunberg JH, Doyle MV, York SM, York CJ. Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc Natl Acad Sci (USA) 1989; 86: 4240–4243.Google Scholar
  100. 100.
    Oldham RK, Foon KA, Morgan AC, et al. Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration J Clin Oncol 1984; 2: 1235–1243.PubMedGoogle Scholar
  101. 101.
    Philben VJ, Jakowatz JG, Beatty BG, et al. The effect of tumor CEA content and tumor size on tissue uptake of indium Ill-labeled anti-CEA monoclonal antibody. Cancer 1986; 57: 571–576.PubMedGoogle Scholar
  102. 102.
    Plummer JM, Goodwin JJ, Osband ME. Successful in vitro immunization of human peripheral blood monocular cells against prostate specific antigens: an approach for antigen specific adaptive immunotherapy of prostatic cancer. J Cell Biochem Sup 1990; 14B: 91.Google Scholar
  103. 103.
    Posnett DN, McGrath H, Tam JP. A novel method for producing anti-peptide antibodies. J Biol Chem 1988; 263:1719–1725.PubMedGoogle Scholar
  104. 104.
    Racz T, Sacks PG, Taylor DL, Schantz SP. Natural killer cell lysis of head and neck cancer. Arch Otolarngol Head Neck Surg 1989; 115: 1322–1328.Google Scholar
  105. 105.
    Ralston S, Hoeprich P, Akita R. Identification and synthesis of the epitope for a human monoclonal antibody which can neutralize human T-cell leukemia/lymphotropic virus Type I.J Biol Chem 1989; 264: 16343–16346.PubMedGoogle Scholar
  106. 106.
    Raychaudhuri S, Saeki Y, Fuji H, et al. Tumor-specific idiotype vaccines. 1. Generation and characterization of internal image tumor antigen. J Immunol 1986; 137: 1743–1749.PubMedGoogle Scholar
  107. 107.
    Reddish M, Ravindranath MH, Brazeau SM, Morton DL. Experientia 1994; 50(7): 648–653.Google Scholar
  108. 108.
    Reeves WC, Brinton LA, Garcia M, et al. Human papillomavirus infection and cervical cancer in Latin America. NEngl J Med 1989; 320: 1437–1441.Google Scholar
  109. 109.
    Reisfeld RA, Schultz G, Cheresh DA. Approaches for immunotherapy of malignant melanoma with monoclonal antibodies. In: Monoclonal Antibodies and Cancer Therapy, edited by RA Reisfeld and S Sell, pp. 173–191. New York, Alan R. Liss, 1985.Google Scholar
  110. 110.
    Rettig WJ, Cordon-Cardo C, Koulos JP, et al. Cell surface antigens of human trophoblast and choriocarcinoma defined by monoclonal antibodies. Int J Cancer 1985; 54: 469–475.Google Scholar
  111. 111.
    Rose TM, Plowman GD, Teplow DB, et al. Primary structure of the human melanoma-associated antigen p97 (melanotransferin) deduced from the mRNA sequence. Proc Natl Acad Sci (USA) 1986; 83: 1261–1265.Google Scholar
  112. 112.
    Roth JA, Ames RS, Restrepo C, et al. Monoclonal antibody 45-2D9 recognizes a cell surface glycoprotein on a human c-Ha-ras transformed cell line (45-342) and a shared epitope on human tumors. J Immunol 1986; 137: 2385.PubMedGoogle Scholar
  113. 113.
    Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI. J Urol 1994; 151(3) 622–628.PubMedGoogle Scholar
  114. 114.
    Savage HE, Rossen RD, Hersh EM, et al. Antibody development to viral and allogeneic tumor cell-associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus-infected tumor cells. Cancer Res 1986; 46: 2127–2133.PubMedGoogle Scholar
  115. 115.
    Schild H, vonHoegen P, Schirrmacher V Modification of tumor cells by a low dose of Newcastle disease virus. Cancer Immunol Immunother 1989; 28: 22–28.PubMedGoogle Scholar
  116. 116.
    Schlom J. Basic principles and applications of monoclonal antibodies in the management of carcinomas: The Richard and Hinda Rosenthal foundation award lecture. Cancer Res 1986; 46: 3225–3238.PubMedGoogle Scholar
  117. 117.
    Schmoll HJ. Ann Oncol 1994; 5 Suppl 3: 115–121.PubMedGoogle Scholar
  118. 118.
    Seigler HF, Wallack MK, Vervaert CE, et al. Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies. J Biol Response Mod 1988; 8: 37–52.Google Scholar
  119. 119.
    Sell S. Cancer markers: past, present and future. In: Monoclonal Antibodies and Cancer Therapy, edited by RA Reisfeld and S Sell. New York, Alan R. Liss, 1985.Google Scholar
  120. 120.
    Sinigaglia R, Guttinger M, Kilgus J, et al. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 1988; 336: 778–780.PubMedGoogle Scholar
  121. 121.
    Sivanandham M, Scoggin SD, Tanaka N, Wallack MK. Cancer Immunol Immunother 1994; 38() 259–264.Google Scholar
  122. 122.
    Srivastava PK, DeLeo AB, and Old LJ. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci (USA) 1986; 83: 3407–3411.Google Scholar
  123. 123.
    Stewart-Tull DES. Immunopotentiating conjugates. Vaccine 1985; 3: 40–44.PubMedGoogle Scholar
  124. 124.
    Tahara H, Zeh JH III, Storkus WJ, et al. Cancer Res 1994; 54(1) 182–189.PubMedGoogle Scholar
  125. 125.
    Tai T, Cahan LD, Tsuchida T, et al , Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 1985; 35: 607–612.PubMedGoogle Scholar
  126. 126.
    Tanaka K, Hayashi H, Hamada C, et al. Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells. Proc Natl Acad Sci (USA) 1986; 83: 8723–8727.Google Scholar
  127. 127.
    Taniguchi N, Lizuka S, Zhe ZN, et al. Measurements of human serum immunoreactive y-glutamyl transpeptidase in patients with malignant tumors using enzyme-linked immunosorbent assay. Cancer Res 1985; 45: 5835–5839.PubMedGoogle Scholar
  128. 128.
    Tepper RI. Cytokines and strategies for anticancer vaccines. Contemporary Oncology 1993; 9: 38–53.Google Scholar
  129. 129.
    Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci (USA) 1979; 76:4350–4354.Google Scholar
  130. 130.
    Townsend SE, Allison JP. Science 1993; 259–262.Google Scholar
  131. 131.
    Uede T, Yamari T, Shijubo N, et al. In vivo factor(s) responsible for CTL induction. Gann Monograph on Cancer Research 1988; 34: 91–106.Google Scholar
  132. 132.
    Ullrich SJ, Robinson EA, Law LW, et al. A mouse tumorspecific transplantation antigen is a heat shock-related protein. Proc Natl Acad Sci (USA) 1986; 83: 3121–3125.Google Scholar
  133. 133.
    Urban JL, Kripke ML, Schreiber H. Stepwise immunologic selection of antigenic variants during tumor growth. J Immunother 1986; 137: 3036–3041.Google Scholar
  134. 134.
    Waldman TA, Davis MM, Bongiovanni KF, et al. Rearrangements of genes for the antigen receptor on Tcells as markers of lineage and clonality in human lymphoid neoplasms. N Engl J Med 1985; 313: 776–783.Google Scholar
  135. 135.
    Wallich R, Bulbuc N, Hammerling G J, et al. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 1985; 315: 301–305.PubMedGoogle Scholar
  136. 136.
    Watt KWK, Lee P-J, Timkulu TM, et al. Human prostatespecific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci (USA) 1986; 83: 3166–3170.Google Scholar
  137. 137.
    Watts TH, Gariepy J, Schoolnik GK, et al. T-cell activation by peptide antigen: Effect of peptide sequence and method of antigen presentation. Proc Natl Acad Sci (USA) 1985; 82: 5480–5484.Google Scholar
  138. 138.
    Weinberg A, Merigan TC. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection: Immunization of guinea pigs with Herpes Simplex virus subunit vaccines. J Immunol 1988; 140: 294–299.PubMedGoogle Scholar
  139. 139.
    Weisenburger TH, Jones PC, Ahn SS, et al. Active specific intralymphatic immunotherapy in metastic malignant melanoma: evidence of clinical response J Biol Resp Modif 1982; 1:57–66.Google Scholar
  140. 140.
    Wettendorff M, Iliopoulos D, Tempero M, et al. Idiotypic cascades in cancer patients treated with monoclonal antibody C017-1A. Proc Natl Acad Sci (USA) 1989; 86: 3787–3791.Google Scholar
  141. 141.
    Wilson IA, Niman HL, Houghten RA, et al. The structure of an antigenic determinant in a protein . Cell 1984; 37: 767–778.PubMedGoogle Scholar
  142. 142.
    Wiseman CL, Rao VS, Kennedy PS, et al. Clinical responses with active specific intralymphatic immunotherapy for cancer-A Phase I-II trial. West J Med 1989; 151:283–288).PubMedGoogle Scholar
  143. 143.
    Yamada G, Hatakeyama M, Fujita T, Taniguchi T. Molecular biology of the interleukin-2 system. Gann Monograph on Cancer Research 1988; 34: 167–178.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • George C. Fareed
    • 1
  • Lynn E. Spitler
    • 2
  2. 2.Jenner Technologies, Inc.,TiburonUSA

Personalised recommendations